1. Home
  2. KALV vs ASIC Comparison

KALV vs ASIC Comparison

Compare KALV & ASIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.79

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

ASIC

Ategrity Specialty Insurance Company Holdings

HOLD

Current Price

$20.67

Market Cap

930.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
ASIC
Founded
N/A
2018
Country
United States
United States
Employees
N/A
203
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
930.6M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
KALV
ASIC
Price
$26.79
$20.67
Analyst Decision
Strong Buy
Buy
Analyst Count
5
4
Target Price
$32.60
$26.75
AVG Volume (30 Days)
5.4M
63.7K
Earning Date
07-09-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,000,000.00
N/A
Revenue This Year
$185.42
$34.21
Revenue Next Year
$59.23
$34.65
P/E Ratio
N/A
$98.60
Revenue Growth
495.66
N/A
52 Week Low
$9.83
$16.35
52 Week High
$26.85
$23.88

Technical Indicators

Market Signals
Indicator
KALV
ASIC
Relative Strength Index (RSI) 74.93 56.25
Support Level $14.25 $20.32
Resistance Level $26.85 $21.04
Average True Range (ATR) 0.07 0.71
MACD -0.19 0.17
Stochastic Oscillator 75.00 69.73

Price Performance

Historical Comparison
KALV
ASIC

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About ASIC Ategrity Specialty Insurance Company Holdings

Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.

Share on Social Networks: